Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07202039 · ClinicalTrials.gov registry record · NA
Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine
A NA study, sponsored by Prisma Health-Upstate.
- Recruiting
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT07202039: Recruiting NA study, sponsored by Prisma Health-Upstate.
NCT07202039 is a NA study that is actively recruiting participants, run by Prisma Health-Upstate. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07202039, a NA study, is actively recruiting participants, sponsored by Prisma Health-Upstate.
- RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
This project aims to investigate the impact of e-cigarette flavors and usage patterns on achieving harm-reduction milestones in a sample of cigarette smokers with opioid use disorder who are taking buprenorphine
Primary Outcome
The average change in mean CPD on a 7-day TLFB assessment from baseline (week 0) to weeks 12
Interventions
- BEHAVIORAL Brief individual counseling sessions
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-04-29 |
| Est. Completion | 2029-06-29 |
| Phase | NA |
What NCT07202039 shows while recruiting
NCT07202039 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Brief individual counseling sessions is the first listed.
NCT07202039 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07202039 about?
NCT07202039 is a clinical study titled "Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine". This project aims to investigate the impact of e-cigarette flavors and usage patterns on achieving harm-reduction milestones in a sample of cigarette smokers with opioid use disorder who are taking buprenorphine
What is the current status of trial NCT07202039?
This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2026-04-29. Estimated completion is 2029-06-29.
What interventions are being tested in trial NCT07202039?
The interventions under investigation include: Brief individual counseling sessions (BEHAVIORAL).
Who is sponsoring clinical trial NCT07202039?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07202039's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI